RetinalGenix Technologies Inc. is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas. The Company's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimerâ€™s disease and Parkinsonâ€™s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. It is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimerâ€™s syndrome dementia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/09/26	US$0.000000	-	3
21/09/26	US$0.000000	-	1
18/09/26	US$0.000000	-	18

Delayed Quote OTC Markets

More quotes

Delayed OTC Markets 20:45:29 16/09/2026 BST			5-day change	1st Jan Change
3.990 ^USD	-0.25%		0.00%	+24.69%

08-14	RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-20	RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	75.19M 66.13M 62.53M 56.72M 107M 7.22B 107M 749M 289M 3.68B 282M 276M 11.83B	P/E 2024	-21.8x	P/E 2025	-24.5x
Enterprise Value	75.72M 66.59M 62.97M 57.12M 107M 7.27B 108M 754M 291M 3.71B 284M 278M 11.92B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	34.7%	Yield 2024 *	-	Yield 2025	-

08-14	RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-20	RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	RetinalGenix Technologies Inc. Auditor Raises 'Going Concern' Doubt	CI
03-26	Retinalgenix Technologies Inc. Announces Resignation of Michael Cory Zwerling as Chief Financial Officer, Effective March 22, 2026	CI
01-14	RetinalGenix Technologies Inc. Reports on Its Science and Mission in Light of New AI-Driven Retinal Mapping Study	CI
12-09	RetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Chief Financial Officer, Effective January 1, 2026	CI
12-09	RetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Interim Chief Operating Officer, Effective January 1, 2026	CI
11-14	RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
01/10/25	RetinalGenix Technologies Inc. and RGEN Inc. Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases	CI
01/10/25	RetinalGenix and RGEN Clinical Genotyping Lab partner to advance early disease detection	RE
19/08/25	RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
27/06/25	RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening	CI

01-14	RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study	GL
12-09	RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO	GL
01/10/25	RetinalGenix Technologies and RGEN Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases	GL
25/09/25	RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care	GL
30/06/25	RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening	AQ

RetinalGenix Technologies Inc. Share Price

Stocks

RTGN

US76133Y1055

Biotechnology & Medical Research

Valuation: RetinalGenix Technologies Inc.

Chart: RetinalGenix Technologies Inc.

Latest news: RetinalGenix Technologies Inc.

Press Releases: RetinalGenix Technologies Inc.

News in other languages: RetinalGenix Technologies Inc.

Quotes and Performance

Price Extremes

Managers and Directors: RetinalGenix Technologies Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	-0.25%
Current month	-0.25%
1 month	-0.25%
3 months	-0.25%
6 months	+24.69%
Current year	+24.69%

1 month	3.99	4
Current year	3.99	4
1 year	3.2	4.01
3 years	0.25	6.36
5 years	0.25	20
10 years	0.25	20

Director	Title	Age	Since
Jerry Katzman CHM	Chairman	73	30/11/2018
Herbert Gould BRD	Director/Board Member	97	31/03/2019
Vinay Mehindru BRD	Director/Board Member	58	25/07/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RETINALGENIX TECHNOLOGIES INC.	-0.25%	0.00%	+12.71%	-11.14%	75.19M
LONZA GROUP AG	+2.64%	+6.45%	+12.39%	+38.40%	47.97B
IQVIA HOLDINGS INC.	+0.32%	+0.68%	+50.35%	+37.44%	44.5B
REVOLUTION MEDICINES, INC.	-0.64%	+5.93%	+343.21%	+623.03%	43.93B
BEONE MEDICINES AG	+1.55%	+0.20%	+10.09%	+98.95%	41.03B
CELLTRION, INC.	+0.51%	-0.61%	+5.18%	+46.87%	29.85B
MEDPACE HOLDINGS, INC.	+0.05%	-0.74%	+23.73%	+151.49%	17.27B
TEMPUS AI, INC.	-0.71%	+8.61%	+7.86%	-	15.34B
EUROFINS SCIENTIFIC SE	+1.76%	+0.85%	+29.47%	+48.42%	15.3B
ASCENDIS PHARMA A/S	+1.85%	-3.06%	-	-	14.82B
Average	+0.67%	+2.22%	+55.00%	+129.18%	27.01B
Weighted average by Cap.	+0.82%	+2.97%	+76.25%	+165.44%

	2024	2025
Net sales	-	-
Net income	-4.32M -3.8M -3.59M -3.26M -6.12M -415M -6.16M -43.03M -16.62M -212M -16.22M -15.87M -680M	-2.43M -2.14M -2.02M -1.83M -3.44M -233M -3.46M -24.18M -9.34M -119M -9.12M -8.92M -382M
Net Debt	518K 456K 431K 391K 734K 49.75M 738K 5.16M 1.99M 25.39M 1.95M 1.9M 81.58M	530K 466K 441K 400K 751K 50.87M 755K 5.28M 2.04M 25.96M 1.99M 1.95M 83.42M